Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$66.00 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources PDF SUMMARY Display this book on your site! Related Titles Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction Combating Tobacco Use in Military and Veteran Populations Other Related Titles Scientific Standards for Studies on Modified Risk Tobacco Products (2012) Board on Population Health and Public Health Practice (BPH) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix B: Chapters 1 and 2 from *Evaluation of Biomarkers andSurrogate Endpoints in Chronic Disease*." Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press, 2012. Please select a format: Page 257   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore Page 257 Front Matter (R1-R20) Summary (1-20) 1 Introduction (21-44) 2 Governance and Conduct of Studies (45-72) 3 Evidence Base and Methods for Studying Health Effects (73-148) 4 Methods for Investigating Addictive Potential (149-190) 5 Methods for Studying Risk Perception and Risk Communication (191-220) 6 Decision Making and Oversight of MRTP Studies: Findings and Recommendations (221-246) Appendix A: Section 911 of the Family Smoking Prevention and Tobacco Control Act of 2009 (247-256) Appendix B: Chapters 1 and 2 from *Evaluation of Biomarkers andSurrogate Endpoints in Chronic Disease* (257-258) [Appendix B] 1 Introduction (259-274) [Appendix B] 2 Review: Evaluating and Regulating Biomarker Use (275-338) Appendix C: Committee Biographies (339-346) Appendix D: Meeting Agendas (347-350)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 257
Appendix B Chapters 1 and 2 from Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease1 1 Institute of Medicine. 2010. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: The National Academies Press. 257

OCR for page 258